Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
Abstract
Purpose: This phase II study investigated the efficacy and tolerability of motesanib, an investigational, highly selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit in advanced medullary thyroid cancer (MTC). Patients and Methods: Patients with locally advanced or metastatic, progressive or symptomatic MTC received motesanib 125 mg/d orally for up to 48 weeks or until unacceptable toxicity or disease progression. The primary end point was objective response by independent review. Other end points included duration of response, progression-free survival, safety, pharmacokinetics, and changes in tumor markers. Results: Of 91 enrolled patients who received motesanib, two (2%) achieved objective response (95% CI, 0.3% to 7.7%); their duration of response was 32 weeks (censored) and 21 weeks (disease progressed). Eighty-one percent of patients had stable disease (48% had durable stable disease ≥ 24 weeks), 8% had disease progression as best response, and 9% were not evaluated; 76% experienced a decrease from baseline in target lesion measurement. Median progression-free survival was 48 weeks (95% CI, 43 to 56 weeks). Among patients with tumor marker analysis, 69 (83%) of 83 and 63 (75%) of 84 had decreased serum calcitonin and carcinoembryonic antigen during treatment, respectively, compared with baseline. The most common treatment-related adverse events were diarrhea (41%), fatigue (41%), hypothyroidism (29%), hypertension (27%), and anorexia (27%). In pharmacokinetic analyses, motesanib trough concentrations were lower compared with differentiated thyroid cancer patients from the same study. Conclusion: Although the objective response rate was low, a significant proportion of MTC patients (81%) achieved stable disease while receiving motesanib.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A substantially increased LT4 dose has been reported in athyreotic patients prescribed tyrosine kinase inhibitors such as imatinib, motesanib, sorafenib, sunitinib, and vandetanib.
“The need for a substantially increased dose of LT4 has been reported in athyreotic patients prescribed tyrosine kinase inhibitors such as imatinib (188), motesanib (189), sorafenib (190), sunitinib, and vandetanib (191).”
From Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014) · cites this paper as [189]
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works
Collett, D. (1991) · Springer eBooks · doi:10.1007/978-1-4899-4475-7 · Cited by 1,952 · see citing works
Sherma, S. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12488-9 · Cited by 926 · see citing works
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E. J., Kim, S., Bycott, P. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 622 · see citing works
Carlson, K. M., Dou, S., Chi, D., Scavarda, N. J., Toshima, K., Jackson, C. E., Wells, S. A., Goodfellow, P. J., & Donis-Keller, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1579 · Cited by 599 · see citing works
Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1714 · Cited by 531 · see citing works
Self-citationMotesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470 · see citing works
Self-citationHypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Desai, J., Yassa, L., Marqusee, E., George, S., Frates, M. C., Chen, M. H., Morgan, J. A., Dychter, S. S., Larsen, P. R., Demetri, G. D., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-9-200611070-00008 · Cited by 402 · see citing works
Bunone, G., Vigneri, P. G., Mariani, L., Butó, S., Collini, P., Pilotti, S., Pierotti, M. A., & Bongarzone, I. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65515-0 · Cited by 395 · see citing works
AACE/AAES MEDICAL/SURGICAL Guidelines for Clinical Practice: Management of Thyroid Carcinoma
Cobin, R. H., Gharib, H., Bergman, D. A., Clark, O. H., Cooper, D. S., Daniels, G. H., Dickey, R. A., Duick, D. S., Garber, J. R., HAY, I. D., et al. (2001) · Endocrine Practice · doi:10.4158/ep.7.3.202 · Cited by 366 · see citing works
Leboulleux, S., Baudin, É., Travagli, J., & Schlumberger, M. J. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02037.x · Cited by 299 · see citing works
Self-citationPolverino, A. J., Coxon, A., Starnes, C. O., Diaz, Z., DeMelfi, T. M., Wang, L., BREADY, J. V., Estrada, J., Cattley, R. C., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4665 · Cited by 286 · see citing works
Somatic mutations in the RET proto‐oncogene in sporadic medullary thyroid carcinoma
Marsh, D. J., Learoyd, D., Andrew, S. D., Krishnan, L., Pojer, R., Richardson, A., Delbridge, L., Eng, C., & Robinson, B. G. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.681503.x · Cited by 278 · see citing works
Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels
Giraudet, A., Vanel, D., Leboulleux, S., Auperin, A., Dromain, C., Chami, L., Tovo, N. N., Lumbroso, J., Lassau, N., Bonniaud, G., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1211 · Cited by 263 · see citing works
Self-citationChang, P. C., & Collett, D. (1993) · Journal of the American Statistical Association · doi:10.2307/2290370 · Cited by 261 · see citing works
Nishino, M., Pusztaszeri, M. P., & Pitman, M. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-60570-8_9 · Cited by 234 · see citing works
Eng, C., & Mulligan, L. M. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)9:2 · Cited by 212 · see citing works
Wong, E., Rosen, L. S., Mulay, M., VanVugt, A., Dinolfo, M., Tomoda, C., Sugawara, M., & Hershman, J. M. (2007) · Thyroid · doi:10.1089/thy.2006.0308 · Cited by 206 · see citing works
A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer
Pennell, N. A., Daniels, G. H., Haddad, R. I., Ross, D. S., Evans, T. L., Wirth, L. J., Fidias, P., Temel, J. S., Gurubhagavatula, S., Heist, R. S., et al. (2007) · Thyroid · doi:10.1089/thy.2007.0120 · Cited by 199 · see citing works
Self-citationRosen, L. S., Kurzrock, R., Mulay, M., Vugt, A. V., Purdom, M., Ng, C. S., Silverman, J., Koutsoukos, A. D., Sun, Y., Bass, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8170 · Cited by 187 · see citing works
Self-citationA Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma
de Groot, J. W. B., Zonnenberg, B. A., van Ufford-Mannesse, P. Q., de Vries, M. M., Links, T. P., Lips, C. J. M., & Voest, E. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0649 · Cited by 179 · see citing works
Surgical Strategy for the Treatment of Medullary Thyroid Carcinoma
Fleming, J. B., Lee, J. E., Bouvet, M., Schultz, P. N., Sherman, S. I., Sellin, R. V., Friend, K. E., Burgess, M. A., Cote, G. J., Gagel, R. F., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199911000-00013 · Cited by 152 · see citing works
Self-citationAkeno-Stuart, N., Croyle, M., Knauf, J. A., Malaguarnera, R., Vitagliano, D., Santoro, M., Stephan, C., Grosios, K., Wartmann, M., Cozens, R. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4605 · Cited by 115 · see citing works
Medullary thyroid carcinoma: Including MEN 2A and MEN 2B syndromes
Quayle, F. J., & Moley, J. F. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20184 · Cited by 92 · see citing works
Medullary Thyroid Cancer: An Immunohistochemical and Humoral Study Using Six Separate Antigens
Pacini, F., Basolo, F., Elisei, R., Fugazzola, L., Cola, A., & Pinchera, A. (1991) · American Journal of Clinical Pathology · doi:10.1093/ajcp/95.3.300 · Cited by 91 · see citing works
Self-citationWells, S. A., Gosnell, J. E., Gagel, R. F., Moley, J. F., Pfister, D. G., Sosa, J. A., Skinner, M., Krebs, A., Hou, J., & Schlumberger, M. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.6018 · Cited by 89 · see citing works
Self-citationde Boer, M. F., van den Borne, B. H. P., Pruyn, J. F. A., Ryckman, R. M., Volovics, L., Knegt, P. P. M., Meeuwis, C. A., Mesters, I., & Verwoerd, C. D. A. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12 · Cited by 82 · see citing works
Fujisawa, T., & Yamaguchi, Y. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3 · Cited by 68 · see citing works
What Is the Most Cost-Effective Population-Based Cancer Screening Program for Chinese Women?
Woo, P., Kim, J. J., & Leung, G. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0210 · Cited by 58 · see citing works
Effect of sorafenib in symptomatic metastatic medullary thyroid cancer
Kober, F., Hermann, M., Handler, A., & Krotla, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14065 · Cited by 51 · see citing works
Rôle of calcitonin in diarrhoea associated with medullary carcinoma of the thyroid.
Cox, T. M., Fagan, E., Hillyard, C. J., Allison, D. J., & CHADWICK, V. S. (1979) · Gut · doi:10.1136/gut.20.7.629 · Cited by 48 · see citing works
Tsai, M. S., Ledger, G. A., Khosla, S., Gharib, H., & Thibodeau, S. N. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.5.7909818 · Cited by 47 · see citing works
Unanswered questions regarding the management of sunitinib-induced hypothyroidism
Garfield, D. H., Hercbergs, A. H., & Davis, P. J. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0998 · Cited by 30 · see citing works
Personalized Thyroid Medicine—The Time Is Now
Davies, T. F. (2007) · Thyroid · doi:10.1089/thy.2007.9998 · Cited by 18 · see citing works
Puberty, Exercise and Bone Health
Rogol, A. D. (2007) · Hormone Research in Paediatrics · doi:10.1159/000098547 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N. Y., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444 · see citing works
Self-citationJonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · see citing works
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,735 · see citing works
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, É., Elisei, R., Jarząb, B., Vasselli, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,556 · see citing works
Self-citationCabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217 · see citing works
Self-citationIndoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 641 · see citing works
Chen, H., Sippel, R. S., O'Dorisio, M. S., Vinik, A. I., Lloyd, R. V., & Pacák, K. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb4f0 · Cited by 591 · see citing works
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550 · see citing works
Self-citationWells, S. A., Gosnell, J. E., Gagel, R. F., Moley, J. F., Pfister, D. G., Sosa, J. A., Skinner, M., Krebs, A. D., Vasselli, J. R., & Schlumberger, M. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6604 · Cited by 518 · see citing works
Self-citationAnti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2009) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 506 · see citing works
Carr, L. L., Mankoff, D. A., Goulart, B., Eaton, K. D., Capell, P. T., Kell, E., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 422 · see citing works
Self-citationTargeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Drilon, A. E. D. C., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.175 · Cited by 409 · see citing works
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Lam, E. T., Ringel, M. D., Kloos, R. T., Prior, T. W., Knopp, M. V., Liang, J., Sammet, S., Hall, N. C., Wakely, P. E., Vasko, V. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0068 · Cited by 378 · see citing works
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pacini, F., Castagna, M. G., Brilli, L., & Pentheroudakis, G. E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq190 · Cited by 351 · see citing works
Self-citationMultiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update
Wells, S. A., Pacini, F., Robinson, B. G., & Santoro, M. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1204 · Cited by 336 · see citing works
Self-citationRecent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 328 · see citing works
Robinson, B. G., Paz-Ares, L. G., Krebs, A. D., Vasselli, J. R., & Haddad, R. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2461 · Cited by 256 · see citing works
Pacini, F., Castagna, M. G., Cipri, C., & Schlumberger, M. J. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.05.002 · Cited by 246 · see citing works
Self-citationHigh Prevalence of RAS Mutations in RET -Negative Sporadic Medullary Thyroid Carcinomas
Moura, M. M., Cavaco, B. M., Pinto, A. E., & Leite, V. A. P. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1921 · Cited by 243 · see citing works
Treatment of advanced thyroid cancer with targeted therapies: ten years of experience
Viola, D., Valerio, L., Molinaro, E., Agate, L., Bottici, V., Biagini, A., Lorusso, L., Cappagli, V., Pieruzzi, L., Giani, C., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-15-0555 · Cited by 190 · see citing works
Self-citationScagliotti, G. V., Vynnychenko, I. O., Park, K., Ichinose, Y., Kubota, K., Blackhall, F. H., Pirker, R., Galiulin, R., Ciuleanu, T., Sydorenko, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4987 · Cited by 184 · see citing works
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series
Ciampi, R., Mian, C., Fugazzola, L., Cosci, B., Romei, C., Barollo, S., Cirello, V., Bottici, V., Marconcini, G., Rosa, P. M., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0207 · Cited by 179 · see citing works
Self-citationThyroid Dysfunction from Antineoplastic Agents
Hamnvik, O. R., Larsen, P. R., & Marqusee, E. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr373 · Cited by 165 · see citing works
2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer
Schlumberger, M. J., Bastholt, L., Dralle, H., Jarząb, B., Pacini, F., & Smit, J. W. A. (2012) · European Thyroid Journal · doi:10.1159/000336977 · Cited by 157 · see citing works
Self-citationUpdates on the Management of Thyroid Cancer
Araque, K., Gubbi, S., & Kłubo-Gwieździńska, J. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1089-7870 · Cited by 162 · see citing works
Boichard, A., Croux, L., Ghuzlan, A. A., Broutin, S., Dupuy, C., Leboulleux, S., Schlumberger, M. J., Bidart, J., & Lacroix, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2092 · Cited by 152 · see citing works
Self-citationTargeting RET Receptor Tyrosine Kinase Activation in Cancer
Phay, J. E., & Shah, M. H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0786 · Cited by 150 · see citing works
Thornton, K. A., Kim, G., Maher, V. E., Chattopadhyay, S., Tang, S. W., Moon, Y. J., Song, P., Marathe, A., Balakrishnan, S., Zhu, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0411 · Cited by 149 · see citing works
Anlotinib as a molecular targeted therapy for tumors (Review)
Gao, Y., Liu, P., & Shi, R. (2020) · Oncology Letters · doi:10.3892/ol.2020.11685 · Cited by 149 · see citing works
Multikinase inhibitors: a new option for the treatment of thyroid cancer
Gild, M. L., Bullock, M., Robinson, B. G., & Clifton-Bligh, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.141 · Cited by 142 · see citing works
Krampitz, G. W., & Norton, J. A. (2014) · Cancer · doi:10.1002/cncr.28661 · Cited by 139 · see citing works
Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives
Ceolin, L., Duval, M. A. D. S., Benini, A. F., Ferreira, C. V., & Maia, A. L. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0574 · Cited by 140 · see citing works
Thyroid Cancer: Risk-Stratified Management and Individualized Therapy
Raue, F., & Frank‐Raue, K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0484 · Cited by 136 · see citing works
Management of advanced medullary thyroid cancer
Hadoux, J., Pacini, F., Tuttle, R. M., & Schlumberger, M. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00337-x · Cited by 133 · see citing works
Self-citationBelli, C., Penault-Llorca, F. M., Ladanyi, M., Normanno, N., Scoazec, J., Lacroix, L., Reis-Filho, J. S., Subbiah, V., Gainor, J. F., Endris, V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.021 · Cited by 125 · see citing works
Current Understanding and Management of Medullary Thyroid Cancer
Roy, M., Chen, H., & Sippel, R. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0053 · Cited by 123 · see citing works
Locati, L. D., Licitra, L. F., Agate, L., Ou, S. I., Boucher, A., Jarząb, B., Qin, S., Kane, M. A., Wirth, L. J., Chen, C., et al. (2014) · Cancer · doi:10.1002/cncr.28766 · Cited by 120 · see citing works
Self-citationBible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Karlin, N. J., Sideras, K., Morris, J. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3713 · Cited by 120 · see citing works
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117 · see citing works
THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma
Baudin, É., Habra, M. A., Deschamps, F., Cote, G. J., Dumont, F., Cabanillas, M. E., Arfi, J., Berdelou, A., Moon, B., Ghuzlan, A. A., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0113 · Cited by 117 · see citing works
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
Sun, Y., Du, F., Gao, M., Ji, Q., Li, Q., Zhang, Y., Guo, Z., Wang, J., Chen, X., Wang, J., et al. (2018) · Thyroid · doi:10.1089/thy.2018.0022 · Cited by 113 · see citing works
Self-citationMultiple endocrine neoplasia type 2: A review
Mathiesen, J. S., Effraimidis, G., Rossing, M., Rasmussen, Å. K., Hoejberg, L., Bastholt, L., Godballe, C., Oturai, P., & Feldt‐Rasmussen, U. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.035 · Cited by 113 · see citing works
Self-citationSorafenib in metastatic thyroid cancer
Capdevila, J., Iglesias, L., Halperín, I., Segura, Á., Martínez‐Trufero, J., Salgado, M. Á. V., Corral, J., Obiols, G., Grande, E., Grau, J. J., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0351 · Cited by 111 · see citing works
RAS proto-oncogene in medullary thyroid carcinoma
Moura, M. M., Cavaco, B. M., & Leite, V. A. P. H. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0070 · Cited by 111 · see citing works
Hong, D. S., Cabanillas, M. E., Wheler, J. J., Naing, A., Tsimberidou, A. M., Ye, L., Waguespack, S. G., Hernández, M., Naggar, A. K. E., Bidyasar, S., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1899 · Cited by 109 · see citing works
Self-citationSorafenib in Metastatic Thyroid Cancer: A Systematic Review
Thomas, L., Lai, S. Y., Dong, W., Feng, L., Dadu, R., Regone, R. M., & Cabanillas, M. E. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0362 · Cited by 106 · see citing works
Management of Medullary Thyroid Cancer
Viola, D., & Elisei, R. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.11.006 · Cited by 104 · see citing works
Self-citationAdvances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers
Sherman, S. I. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0923 · Cited by 104 · see citing works
Self-citationUpdate on the Cytologic and Molecular Features of Medullary Thyroid Carcinoma
Pusztaszeri, M. P., Bongiovanni, M., & Faquin, W. C. (2013) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000004 · Cited by 101 · see citing works
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
Tirrò, E., Martorana, F., Romano, C., Vitale, S. R., Motta, G., Gregorio, S. D., Massimino, M., Pennisi, M. S., Stella, S., Puma, A., et al. (2019) · Genes · doi:10.3390/genes10090709 · Cited by 101 · see citing works
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications
Jin, S., Borkhuu, O., Bao, W., & Yang, Y. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2480w · Cited by 100 · see citing works
Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy
Plaza-Menacho, I., Mologni, L., & McDonald, N. Q. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.03.032 · Cited by 94 · see citing works
Evolving molecularly targeted therapies for advanced-stage thyroid cancers
Bible, K. C., & Ryder, M. M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.19 · Cited by 93 · see citing works
ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors
Illouz, F., Braun, D., Briet, C., Schweizer, U., & Rodien, P. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0198 · Cited by 93 · see citing works
Blumenschein, G. R., Kabbinavar, F. F., Menon, H., Mok, T. S. K., Stephenson, J. R., Beck, J. T., Lakshmaiah, K., Reckamp, K. L., Hei, Y., Kracht, K., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq731 · Cited by 92 · see citing works
Self-citationNew treatment modalities in advanced thyroid cancer
Kapiteijn, E., Schneider, T. C., Morreau, H. M., Gelderblom, H. A. J., Nortier, J. W. R., & Smit, J. W. A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr117 · Cited by 91 · see citing works
Bass, M., Sherman, S. I., Mj, S., Davis, M. T., Kivman, L., Khoo, H.-M., Notari, K. H., Peach, M. L., Hei, Y.-J., & Patterson, S. D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0947 · Cited by 90 · see citing works
Self-citationKinases as targets in the treatment of solid tumors
Giamas, G., Man, Y. L., Hirner, H., Bischof, J., Kramer, K. M., Khan, K., Ahmed, S. S. L., Stebbing, J., & Knippschild, U. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.011 · Cited by 89 · see citing works
Tyrosine Kinase Inhibitor–Induced Thyroid Disorders: A Review and Hypothesis
Makita, N., & Iiri, T. (2013) · Thyroid · doi:10.1089/thy.2012.0456 · Cited by 89 · see citing works
Vandetanib for the Treatment of Medullary Thyroid Cancer
Chau, N. G., & Haddad, R. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2353 · Cited by 86 · see citing works
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Capdevila, J., & Stjepanovic, N. (2014) · Biologics: Targets and Therapy · doi:10.2147/btt.s39381 · Cited by 85 · see citing works
Targeted therapies for thyroid tumors
Sherman, S. I. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.165 · Cited by 84 · see citing works
Self-citationVerbeek, H. H. G., Alves, M. M., de Groot, J. B., Osinga, J., Plukker, J. T. M., Links, T. P., & Hofstra, R. M. W. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2381 · Cited by 82 · see citing works
Salaün, P., Campion, L., Bournaud, C., Faivre-Chauvet, A., Vuillez, J.-P., Taïeb, D., Ansquer, C., Rousseau, C., Borson‐Chazot, F., Bardet, S., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.101865 · Cited by 82 · see citing works
Endocrine side effects of broad-acting kinase inhibitors
Lodish, M. B., & Stratakis, C. A. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0082 · Cited by 82 · see citing works
Wells, S. A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0325 · Cited by 79 · see citing works
Current Update on Medullary Thyroid Carcinoma
Ganeshan, D., Paulson, E. K., Duran, C., Cabanillas, M. E., Busaidy, N. L., & Charnsangavej, C. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.10370 · Cited by 77 · see citing works
Novel anti-angiogenic therapeutic strategies in colorectal cancer
Tampellini, M., Sonetto, C., & Scagliotti, G. V. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1161754 · Cited by 77 · see citing works
Targeted therapy of thyroid cancer
Sherman, S. I. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.003 · Cited by 76 · see citing works
Self-citationLow Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid Cancer
Romei, C., Ugolini, C., Cosci, B., Torregrossa, L., Vivaldi, A., Ciampi, R., Tacito, A., Basolo, F., Materazzi, G., Miccoli, P., et al. (2012) · Thyroid · doi:10.1089/thy.2011.0358 · Cited by 74 · see citing works
Self-citationHesselink, E. N. K., Steenvoorden, D. P. T., Kapiteijn, E., Corssmit, E. P. M., van der Horst‐Schrivers, A. N. A., Lefrandt, J. D., Links, T. P., & Dekkers, O. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0788 · Cited by 68 · see citing works
Biomarkers for Anti-Angiogenic Therapy in Cancer
Wehland, M., Bauer, J. W., Magnusson, N. E., Infanger, M., & Grimm, D. G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14059338 · Cited by 64 · see citing works
Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review
Albero, A., Lopéz, J. E., Torres, A., de la Cruz‐Merino, L., & Hernández, T. M. (2016) · Endocrine Related Cancer · doi:10.1530/erc-15-0194 · Cited by 64 · see citing works
Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies
Grande, E., Díez, J. J., Zafón, C., & Capdevila, J. (2012) · Journal of Thyroid Research · doi:10.1155/2012/847108 · Cited by 63 · see citing works
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma
Heilmann, A. M. F., Subbiah, V., Wang, K., Sun, J., Elvin, J. A., Chmielecki, J., Sherman, S. I., Murthy, R., Busaidy, N. L., Subbiah, I. M., et al. (2016) · Oncology · doi:10.1159/000445978 · Cited by 63 · see citing works
Self-citationThyroid dysfunctions induced by tyrosine kinase inhibitors
Fallahi, P., Ferrari, S. M., Vita, R., Di Domenicantonio, A., Corrado, A., Benvenga, S., & Antonelli, A. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.913021 · Cited by 60 · see citing works
The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors
Ye, L., Santarpia, L., & Gagel, R. F. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0031 · Cited by 60 · see citing works
Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
BOER, R. D., & Hart, C. D. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s27671 · Cited by 59 · see citing works
New therapies for dedifferentiated papillary thyroid cancer
Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58 · see citing works
Progresses Toward Precision Medicine inRET-altered Solid Tumors
Belli, C., Anand, S. K., Gainor, J. F., Penault-Llorca, F. M., Subbiah, V., Drilon, A. E. D. C., André, F., & Curigliano, G. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1587 · Cited by 58 · see citing works
Thyroid cancer: pathogenesis and targeted therapy
Liebner, D. A., & Shah, M. H. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018811419889 · Cited by 57 · see citing works
Wang, Y., Kathawala, R. J., Zhang, Y., Patel, A. S., Kumar, P., Shukla, S., Fung, K. L., Ambudkar, S. V., Talele, T. T., & Chen, Z. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.006 · Cited by 56 · see citing works
New Targeted Therapies for Thyroid Cancer
Antonelli, A., Fallahi, P., Ferrari, S. M., Ruffilli, I., Santini, F., Minuto, M. N., Galleri, D., & Miccoli, P. (2011) · Current Genomics · doi:10.2174/138920211798120808 · Cited by 53 · see citing works
Targeted Therapy for Medullary Thyroid Cancer: A Review
Priya, S. R., Dravid, C. S., Digumarti, R., & Dandekar, M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00238 · Cited by 52 · see citing works
Choroidal and Orbital Metastases from Thyroid Cancer
Bešič, N., & Lužnik, Z. (2012) · Thyroid · doi:10.1089/thy.2012.0021 · Cited by 51 · see citing works
Development of RET Kinase Inhibitors for Targeted Cancer Therapy
Mologni, L. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794088308 · Cited by 51 · see citing works
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer
Hadoux, J., & Schlumberger, M. J. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.04.009 · Cited by 51 · see citing works
Self-citationCohen, E. E. W., Tortorici, M. A., Kim, S., Ingrosso, A., Pithavala, Y. K., & Bycott, P. W. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2604-8 · Cited by 50 · see citing works
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
Matrone, A., Gambale, C., Prete, A., & Elisei, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.864253 · Cited by 51 · see citing works
Self-citationStrosberg, J. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.11.009 · Cited by 48 · see citing works
Tyrosine kinase inhibitors and the thyroid
Sherman, S. I. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.08.001 · Cited by 49 · see citing works
Self-citationMedical management of metastatic medullary thyroid cancer
Maxwell, J. E., Sherman, S. K., O’Dorisio, T. M., & Howe, J. R. (2014) · Cancer · doi:10.1002/cncr.28858 · Cited by 48 · see citing works
Self-citationPrognostic and Predictive Markers in Medullary Thyroid Carcinoma
Erović, B. M., Kim, D. H., Cassol, C. A., Goldstein, D. P., Irish, J. C., Asa, S. L., & Mete, Ö. (2012) · Endocrine Pathology · doi:10.1007/s12022-012-9225-8 · Cited by 48 · see citing works
Schulten, H.-J., Al-Maghrabi, J. A., Alghamdi, K. A., Salama, S., Almuhayawi, S. M., Chaudhary, A., Hamour, O. A., Abuzenadah, A. M., Gari, M. A., & Al-Qahtani, M. H. (2011) · PubMed · Cited by 48 · see citing works
Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma
Almeida, M. Q., & Hoff, A. O. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328351c71a · Cited by 48 · see citing works
Lorusso, L., Pieruzzi, L., Biagini, A., Sabini, E., Valerio, L., Giani, C., Passannanti, P., Contillo, B. P., Battaglia, V., Mazzeo, S., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s84625 · Cited by 47 · see citing works
Self-citationChan, D. B. Y., Zheng, Y., Tyner, J. W., Chng, W. J., Chien, W. W., Gery, S., Leong, G., Braunstein, G. D., & Koeffler, H. P. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1465-6 · Cited by 47 · see citing works
RetractedAdvances in thyroid cancer treatment: latest evidence and clinical potential
Alonso‐Gordoa, T., Díez, J. J., Durán, M., & Grande, E. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014551936 · Cited by 46 · see citing works
Long-Term Follow-up in Medullary Thyroid Carcinoma
Raue, F., & Frank‐Raue, K. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-22542-5_10 · Cited by 46 · see citing works
Metastatic medullary thyroid carcinoma: a new way forward
Angelousi, A., Hayes, A. R., Chatzellis, E., Kaltsas, G. A., & Grossman, A. B. (2022) · Endocrine Related Cancer · doi:10.1530/erc-21-0368 · Cited by 45 · see citing works
- Authors
- Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., Eschenberg, M. J., Sun, Y.-N., Juan, T., Stepan, D. E., & Sherman, S. I.
- Affiliations
- University of Siena (IT)
- From the Institut Gustave Roussy, University Paris Sud, Villejuif; Centre Léon Bérard, Lyon, France; University of Pisa, Pisa; Istituto Nazionale dei Tumori, Milan; University of Siena, Siena, Italy; Odense University Hospital, Odense, Denmark; Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Université Catholique de Louvain, Brussels, Belgium; Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Amgen, Thousand...
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2009-08-10
- Volume
- 27
- Issue
- 23
- Pages
- 3794-3801
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2112475888
- Cited by
- 340
- References
- 35
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 6 · 2022: 8 · 2021: 10 · 2020: 14 · 2019: 12 · 2018: 11 · 2017: 14 · 2016: 22 · 2015: 26 · 2014: 38 · 2013: 36 · 2012: 46
- FWCI
- 33.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
- Keywords
- motesanib, medullary thyroid carcinoma, metastatic thyroid cancer, VEGFR inhibitors, platelet-derived growth factor receptor, KIT inhibitors, tyrosine kinase inhibitors, progression-free survival, stable disease, calcitonin, carcinoembryonic antigen, pharmacokinetics, adverse events, diarrhea, hypothyroidism
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Female, Humans, Indoles, Male, Middle Aged, Niacinamide, Oligonucleotides, Thyroid Neoplasms, Treatment Outcome, Receptors, Platelet-Derived Growth Factor, Carcinoma, Medullary, Proto-Oncogene Proteins c-kit, Receptors, Vascular Endothelial Growth Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
